CKD 的新型疗法
目前正在对许多新型药物进行研究，以减缓 CKD 的进展。大部分研究都集中在糖尿病肾病；但是一些小型临床试验发现某些药物对于非糖尿病肾病有一定获益。抗纤维化药物（例如曲尼司特）已显示出可缓解肾功能的降低并减少蛋白尿；但当在心脏试验中应用大剂量时，一直存在关于其对肝脏和肾脏副作用的担心。[84]Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009 Jul;5(7):375-83.http://www.ncbi.nlm.nih.gov/pubmed/19455178?tool=bestpractice.com针对糖胺聚糖代谢的药物均显示出在减少蛋白尿方面的短期疗效，例如舒洛地特、晚期糖基化终末产物 (AGE) 抑制剂、以及抗炎药物（例如己酮可可碱）。[84]Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009 Jul;5(7):375-83.http://www.ncbi.nlm.nih.gov/pubmed/19455178?tool=bestpractice.com[85]Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015 Dec 3;9:6275-83.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671764/http://www.ncbi.nlm.nih.gov/pubmed/26664049?tool=bestpractice.com[86]Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018 Jun;42(3):188-95.https://e-dmj.org/DOIx.php?id=10.4093/dmj.2017.0105http://www.ncbi.nlm.nih.gov/pubmed/29885110?tool=bestpractice.com[87]Leporini C, Pisano A, Russo E, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2016 May;107:315-32.http://www.ncbi.nlm.nih.gov/pubmed/26995301?tool=bestpractice.com这些药物在大型随机临床试验中的表现如何还有待观察。目前为止，还没有批准新型疗法用于 CKD 的治疗。
